Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Oncotect Inc. currently manages 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This action is assigned to 1 distinct examiner, FAN, WEIHUA, who is the busiest examiner for the portfolio. The prosecution activity is concentrated in 1 distinct art unit, indicating a specific technical focus for the company's current filing.
The portfolio's progress depends on the resolution of 1 pending office action. FAN, WEIHUA is responsible for 1 pending action, making this examiner the sole official currently reviewing the company's biotechnology innovations. The presence of 1 distinct art unit suggests that the legal strategy can be highly specialized for that unit's standards. Practitioners should prioritize the response to this 1 pending action to move the application toward issuance in the Biotechnology & Pharmaceuticals sector.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| FAN, WEIHUA | 1 | 83.3% | +12.7% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18585626 | CANCER SCREENING IN COMPANION ANIMALS | FAN, WEIHUA | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18585626 | CANCER SCREENING IN COMPANION ANIMALS | FAN, WEIHUA | — |
| Art Unit | Apps |
|---|---|
| 1663 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18585626 | CANCER SCREENING IN COMPANION ANIMALS | FAN, WEIHUA | 1663 | §101§102§112 | Non-Final OA | — | Pending | Feb 23, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialOncotect Inc. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Weihua Fan has the most, with 1 of Oncotect Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
